Yahoo Finance Curis, Upcoming SITC Meeting, Aurigene Collaboration and Analysts Review
NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.
Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. Aurigene Discovery Technologies Ltd, a wholly-owned subsidiary of India based Pharma Major, Dr. Reddy's Laboratories Ltd. Aurigene has commercial rights to the program in India and Russia in addition to milestones, royalty’s other commercial supply rights globally.
How strong is the CRIS and Aurigene alliance, analysts target price, financial review READ MORE
Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/curis/
Curis is scheduled to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit on Nov. 10, 2017. In an oral presentation at the SITC Meeting, researchers will provide updated preliminary clinical trial data from the Phase 1 dose escalation stage of CA-170, a small oral molecule targeting the immune checkpoints PDL-1 and VISTA. Also, preclinical data related to combination therapy with CA-327, an oral small molecule PDL-1, VISTA and TIM-3 immune checkpoint antagonist, will be provided in a poster presentation.
The drug has already presented encouraging results with evidence of tumor shrinkage and multiple patients remaining on drug treatment for extended periods, along with signals for biomarkers of immune modulation in patient blood and tumor samples, validates that fact that the program continues to move in the right direction.
Get more details of the upcoming SITC presentation and a pipeline review here READ MORE
Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/curis/
Disclosure
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source